Information Journal Paper
APA:
Copy. (2017). Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, openlabel, randomised phase 2– 3 trial. LANCET ONCOLOGY, 18(3), 357-370. SID. https://sid.ir/paper/764527/en
Vancouver:
Copy. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, openlabel, randomised phase 2– 3 trial. LANCET ONCOLOGY[Internet]. 2017;18(3):357-370. Available from: https://sid.ir/paper/764527/en
IEEE:
Copy, “Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, openlabel, randomised phase 2– 3 trial,” LANCET ONCOLOGY, vol. 18, no. 3, pp. 357–370, 2017, [Online]. Available: https://sid.ir/paper/764527/en